Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has released interim clinical data for its Phase II non-muscle invasive bladder cancer study indicating complete response rates exceeding International Bladder Cancer Group recommendations at various time points. The study, designed to evaluate the safety and efficacy
Full Story >>
Vote
+11